NewAmsterdam Pharma Company N.V.
IPONewAmsterdam Pharma: Science-Backed and Patient-Focused
Public · Naarden, Netherlands · Founded 2019 · $196.0M raised
- Headquarters
- Naarden
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- newamsterdampharma.com
- Total Funding
- $196.0M
- Last Round
- $196.0M Series AJan 2021
- Rounds
- 1
- Type
- Public
About
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, a once-daily oral therapy targeting LDL cholesterol reduction in patients with cardiovascular disease. The company is advancing a late-stage clinical program including the BROADWAY phase 3 trial and combination approaches with statins and other lipid-lowering agents.
Summary
NewAmsterdam Pharma Company N.V. is a Biotech company based in Naarden, Netherlands, founded in 2019. It has raised $196.0M in total across 1 round, most recently a $196.0M Series A round in Jan 2021. Investors include Frazier Healthcare, Forbion Capital Partners and Morningside Group.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...